Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
Sol-Gel Technologies completed last patient last visit in its pivotal Phase 3 trial (SGT-610-01) of SGT-610 (patidegib gel, 2%) for preventing new basal cell carcinoma lesions in adults with Gorlin syndrome, with top-line results on track for late November 2026. The randomized, double-blind, vehicle-controlled study enrolled 113 patients, of whom 102 completed 12 months of treatment; the primary endpoint is the number of new facial BCCs at month 12, with surgically eligible BCCs as a secondary endpoint. The company is proceeding to database lock and statistical analysis, and patients, investigators and Sol-Gel remain blinded to treatment assignment until the readout.
Key figures
- Drug Name
- SGT-610 (patidegib gel, 2%)
- Phase Of Trial
- Phase 3
- Primary endpoint
- number of new BCCs on the face at month 12
- Patients enrolled
- 113
- Patients completed
- 102
- Secondary endpoint
- number of new surgically eligible BCCs (SEBCCs)
- Topline results timing
- late November 2026
- Treatment duration months
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.